Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes
Number needing to change treatment · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in number needing to change treatment compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (low certainty).
1 finding from 1 review
- Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes onlyRR 0.91 [0.78, 1.05]10 studies · 3652 participantsLow